These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23886183)

  • 1. Pitfalls in reimbursement decisions for oncology drugs in South Korea: need for addressing the ethical dimensions in technology assessment.
    Cho E; Park EC; Kang MS
    Asian Pac J Cancer Prev; 2013; 14(6):3785-92. PubMed ID: 23886183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight-year experience of using HTA in drug reimbursement: South Korea.
    Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
    Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations.
    Kolasa K; Kalo Z; Zah V
    Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):483-8. PubMed ID: 27467881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Health Technology Assessment in Drug Policies: Korea.
    Bae EY
    Value Health Reg Issues; 2019 May; 18():24-29. PubMed ID: 30419447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
    Kwon SH; Park SK; Byun JH; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):411-419. PubMed ID: 28019130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
    Maynou L; Cairns J
    Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revealing and acknowledging value judgments in health technology assessment.
    Hofmann B; Cleemput I; Bond K; Krones T; Droste S; Sacchini D; Oortwijn W
    Int J Technol Assess Health Care; 2014 Dec; 30(6):579-86. PubMed ID: 25816823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EXPLORING VALUES OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES USING REFLECTIVE MULTICRITERIA AND RARE DISEASE CASE.
    Goetghebeur MM; Wagner M; Samaha D; O'Neil W; Badgley D; Castro-Jaramillo H; Abrishami P; Sarria-Santamera A; Cleemput I; Tringali M
    Int J Technol Assess Health Care; 2017 Jan; 33(4):504-520. PubMed ID: 29019295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methodological guidance documents for evaluation of ethical considerations in health technology assessment: a systematic review.
    Assasi N; Schwartz L; Tarride JE; Campbell K; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):203-20. PubMed ID: 24625039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
    Kawalec P; Sagan A; Pilc A
    Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
    Pauwels K; Huys I; De Nys K; Casteels M; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
    Eckermann S; Willan AR
    Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of health technology assessment reports on decision making in Austria.
    Zechmeister I; Schumacher I
    Int J Technol Assess Health Care; 2012 Jan; 28(1):77-84. PubMed ID: 22233544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of the pan-Canadian Pharmaceutical Alliance: An Observational Analysis.
    Rocchi A; Mills F
    J Popul Ther Clin Pharmacol; 2018 Aug; 25(2):e12-e22. PubMed ID: 30725539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to introduce more (or better) ethical arguments in HTA?
    Schokkaert E
    Int J Technol Assess Health Care; 2015 Jan; 31(3):111-2. PubMed ID: 26044817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis.
    Kawalec P; Malinowski KP
    Health Policy; 2016 Nov; 120(11):1240-1248. PubMed ID: 28029415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.